

---

## From the Editor



Debu Tripathy, MD  
Editor-in-Chief

Last year, ASCO cited transformation in the treatment of chronic lymphocytic leukemia (CLL) as a hallmark achievement. As you will read in this issue of *AJHO*, there is good reason for this designation. Newer immunotherapy drugs obinutuzumab and ofatumumab delay progression of first-line CLL by more than one year when combined with chemotherapy, and may be better options for older patients in comparison with standard CLL therapies. Coupled with novel oral targeted therapies such as ibrutinib and idelalisib for relapsed disease, these drugs have truly changed the therapeutic landscape.

It is estimated that there are slightly less than 120,000 individuals in the U.S. living with CLL, many of whom are older individuals, making more effective and less toxic therapies particularly welcome. Nearly 19,000 new cases of CLL are expected this year, and while survival rates vary, this can, in many cases, be considered a chronic disease, as the 5-year survival rate is about 80%, with a trend toward improvement in the last few years. We have learned more about the biology of CLL, with prognostic indices such as *IGHV* mutation status, fluorescence in situ hybridization, ZAP-70, CD38, and  $\beta$ 2-microglobulin increasingly being used for decision-making. Newer pharmacological approaches have emerged through our understanding of signaling pathway components such as Bruton's tyrosine kinase (BTK) and specific PI3K isoforms, as well as newer targetable receptors such as CD23 that added to the CD20-based antibodies in existence for some time. Novel drugs targeting Bcl-2 and older immunomodulatory drugs such as lenalidomide also hold potential for refractory disease.

Cancer therapies often come in large quantum leaps for a particular disease, as we witnessed at the turn of the century for breast and colorectal cancers, followed by significant advances in lung cancer, then in melanoma, and more recently for multiple myeloma and CLL. We hope to see this trend continue—with more effective and better-tolerated drugs—as evidenced by how we manage CLL all the way from diagnosis through frontline therapies and beyond.

---

## EDITORIAL STAFF

### Editor-in-Chief

Debu Tripathy, MD  
*Professor and Chair*  
*Department of Breast Medical Oncology*  
*The University of Texas*  
*MD Anderson Cancer Center*  
*Houston, TX*

### Associate Editor

Jason J. Luke, MD, FACP  
*Assistant Professor of Medicine*  
*University of Chicago*  
*Chicago, IL*

### Managing Editor

Howard Whitman  
[hwhitman@ajho.com](mailto:hwhitman@ajho.com)

### Art Director

Nicole Martino

### Editorial Offices

Physicians' Education Resource®, LLC  
666 Plainsboro Road, Ste 356  
Plainsboro, NJ 08536  
(609) 378-3701



### President

Phil Talamo, CHCP

### Medical Director

Michael Perlmutter, PharmD, MS



MH

Michael J. Hennessy Associates, Inc.

---

## CORPORATE OFFICERS

### Chairman and CEO

Michael J. Hennessy, Sr

### Vice Chairman

Jack Lepping

### President

Mike Hennessy, Jr

### Chief Operating Officer and Chief Financial Officer

Neil Glasser, CPA/CFE

### Executive Vice President and General Manager

John Maglione

### Vice President, Digital Media

Jung Kim

### Chief Creative Officer

Jeff Brown

### Human Resource Director

Shari Lundenberg